Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on STOBART GROUP LTD. We currently have 7 research reports from 3 professional analysts.
|23Mar17 07:10||RNS||Eddie Stobart Logistics: Intention to Float on AIM|
|07Mar17 17:22||RNS||Director/PDMR Shareholding|
|07Mar17 17:22||RNS||Director/PDMR Shareholding Replacement|
|07Mar17 17:21||RNS||Director/PDMR Shareholding Replacement|
|02Mar17 07:00||RNS||Director/PDMR Shareholding|
|02Mar17 07:00||RNS||Trading Update and Quarterly Dividend|
|28Feb17 07:00||RNS||Director/PDMR Shareholding|
Frequency of research reports
Research reports on
STOBART GROUP LTD
STOBART GROUP LTD
Disposal-driven returns plus underlying growth
10 Nov 16
We were, on balance, reassured by Stobart’s interim results. The 7.8% yield, supported by the continuing disposal plan, gives equity holders more than enough compensation before operations in Energy and Aviation fully ramp up to their FY19e/CY18 objectives. We adjust our near-term forecasts upwards slightly to reflect the observed H117 margin expansion, but leave our FY19 target year estimates largely unchanged. We believe in the deliverability of Stobart’s FY19e growth targets but, in the case of the Aviation business, we would be further reassured by concrete evidence of passenger growth.
Overview of Operations
08 Jul 16
Stobart Group is a UK based infrastructure and support service business operating in the biomass energy, aviation and railway maintenance sectors. It also holds investments in a property and logistics portfolio. Objectives are to develop and expand beyond the core logistics business, through penetration of the biomass market, as well as creating opportunities to drive value, with a strategic focus on growth areas such as aviation.
14 Jun 16
We believe FY16 marked a turning point for Stobart, as its Energy (biomass) and Aviation (Southend Airport) businesses began to make meaningful progress on their ambitious FY19 targets. Improving returns on these drive our three-year EBITDA CAGR for Stobart Group to 25% by FY18. However, continuing upside from monetising its significant land bank is equally important. Land disposals have paid for Stobart’s dividend while its operating activities have been ramping up. With both operational and investment returns driving improving cash flow, we are optimistic about Stobart’s outlook and ascribe a fair value of £1.35 to the stock.
Hybridan - Small Cap Wrap
01 Jun 16
ALSP* Board Changes, COMS Contract Win, CNS Contract Win, CCS University Partnership, DEMG announces results of ODM trial, ESP acquisition in Leicester, EZH Interim Results, EVG results, FEVR Trading Update, FDEV Update, INS acquisition, MMH Acquisition, MMX Launch, MXCP Placing, OPTI* Patent Filling, PINN Acquisition, PLI* Bought Deal, SAR* Clinical Trial, STOB Deal Completion, TERN Acquisition, TMT* Investments
N+1 Singer - Morning Song 21-03-2017
21 Mar 17
accesso Technology (ACSO LN) Full year results in line, but key trading months still ahead | Augean (AUG LN) Double digit growth in ’16, good start to ‘17 | Earthport (EPO LN) Interims show continued top line strength | Goals Soccer Centres (GOAL LN) Good momentum under new team. It’s now all about delivery | IQE (IQE LN) FY’16 results prompt further upgrades | Microsaic Systems (MSYS LN) Challenges in 2016, strategy remains in place | mporium Group (MPM LN) Funds raised to help execute strategy | RhythmOne (RTHM LN) Dawn of the independents | ScS Group (SCS LN) Strong progress on key growth initiatives albeit comps now toughen | Sinclair Pharma (SPH LN) FY results: EBITDA ahead, Instalift™ gaining pace | Vectura Group (VEC LN) FY (9-month) results
N+1 Singer - N1S Trend spotting - Strategy update
08 Mar 17
In this new product we present some strategy theme updates arising out of our latest analysis of macro trends and economic data and our innovative Quant work. We also look at upcoming events and suggest topping up on some of our Best Ideas for 2017.
N+1 Singer - Augean - Double digit growth in ’16, good start to ‘17
21 Mar 17
Augean reported another year of double digit growth for 2016, with profits in line with our forecasts. Sales grew by 21% excluding landfill tax, while adjusted PBT grew by 18% to £7.1m before amortisation of acquired intangibles. DPS was increased by 54% to 1.0p, 25% ahead of our estimate. The business units made further strategic progress, with revenues from their top 20 customers increasing from 42% to 43% of the total, of which 88% was under contract or a framework agreement, increasing forward visibility. There has been an encouraging start to 2017 and management is confident of delivering another year of profits growth. The shares trade on undemanding single digit multiples, offering good value.
Scott deal puts spotlight back on corporate strategy and valuation
17 Mar 17
The acquisition of Scott Safety by 3M announced yesterday is not a huge surprise but it puts the spotlight back on (1) Avon’s corporate strategy as two strong competitors merge and (2) Avon’s break-up valuation given the rich multiple (12.9x EBITDA) being paid by 3M. Avon and other competitors, particularly MSA Safety, cannot ignore the fact that Scott, which is the leader in SCBA (self-contained breathing apparatus) market and 3M, which derives the bulk of sales from industrial hard hats and masks, would together have the most comprehensive portfolio of products in the PPE (Personal Protective Equipment) market. The good news for investors is that if we were to apply similar EBITDA multiple, then Avon’s Protection & Defence business alone would account for the entire market cap. In effect, at the current share price, investors are getting the Dairy business for free. Our sum-of-the parts model now values the shares at 1,279p, up 7% compared with 1,200p previously.
N+1 Singer - Morning Song 22-03-2017
22 Mar 17
Carador Income Fund (CIFU LN) Premium rating restored, high levels of refinancing activity | Cello Group (CLL LN) Outlook getting brighter – watch Pulsar | Eckoh (ECK LN) Largest ever US secure payments win | eg solutions (EGS LN) Full year results in line | Futura Medical (FUM LN) Licensing deal for CSD500 in Portugal | Verona Pharma (VRP LN) Global agreement with QuintilesIMS to support development of RPL554 | Xaar (XAR LN) 2016 results slightly ahead, reduced visibility in 2017